IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr

Total Income in Q2 FY25 stood at Rs. 532.18 crore

Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr

Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24

Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr

The pharma market is showing encouraging signs of improvement, positioning us well for future growth

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Ami Organics accredited Gold Medal by EcoVadis

The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023

Ami Organics inks agreement with Fermion for two additional APIs

The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25

Ami Organics inaugurates new API manufacturing facility

This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment